Aclaris Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Aclaris Therapeutics, Inc. (ACRS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number of 5.89 million shares as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 5.89M shares.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 5.75M shares.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 4.17M shares.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 4.36M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number |
|---|---|
| 2026-06-30 | 5.89M shares 10-Q · filed 2026-08-06 |
| 2026-03-31 | 5.75M shares 10-Q · filed 2026-05-07 |
| 2025-12-31 | 4.17M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 4.36M shares 10-Q · filed 2025-11-06 |
| 2025-06-30 | 4.51M shares 10-Q · filed 2025-08-07 |
| 2025-03-31 | 4.41M shares 10-Q · filed 2025-05-08 |
| 2024-12-31 | 3.56M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 3.51M shares 10-Q · filed 2024-11-06 |
| 2024-06-30 | 3.53M shares 10-Q · filed 2024-08-07 |
| 2024-03-31 | 3.70M shares 10-Q · filed 2024-05-07 |
| 2023-12-31 | 2.88M shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 3.19M shares 10-Q · filed 2023-11-06 |
| 2023-06-30 | 3.05M shares 10-Q · filed 2023-08-07 |
| 2023-03-31 | 2.96M shares 10-Q · filed 2023-05-08 |
| 2022-12-31 | 2.35M shares 10-K · filed 2023-02-23 |
| 2022-09-30 | 2.31M shares 10-Q · filed 2022-11-08 |
| 2022-06-30 | 2.52M shares 10-Q · filed 2022-08-03 |
| 2022-03-31 | 2.60M shares 10-Q · filed 2022-05-10 |
| 2021-12-31 | 2.20M shares 10-K · filed 2022-02-24 |
| 2021-09-30 | 2.18M shares 10-Q · filed 2021-11-02 |
| 2021-06-30 | 2.04M shares 10-Q · filed 2021-08-05 |
| 2021-03-31 | 2.08M shares 10-Q · filed 2021-05-07 |
| 2020-12-31 | 1.84M shares 10-K · filed 2021-02-25 |
| 2020-09-30 | 1.96M shares 10-Q · filed 2020-11-04 |
| 2020-06-30 | 1.90M shares 10-Q · filed 2020-08-07 |
| 2020-03-31 | 2.12M shares 10-Q · filed 2020-05-07 |
| 2019-12-31 | 2.14M shares 10-K · filed 2020-02-25 |
| 2019-09-30 | 2.28M shares 10-Q · filed 2019-11-07 |
| 2019-06-30 | 2.21M shares 10-Q · filed 2019-08-08 |
| 2019-03-31 | 2.21M shares 10-Q · filed 2019-05-08 |
| 2018-12-31 | 1.91M shares 10-K · filed 2019-03-18 |
| 2018-09-30 | 1.54M shares 10-Q · filed 2018-11-06 |
| 2018-06-30 | 1.38M shares 10-Q · filed 2018-08-03 |
| 2018-03-31 | 1.27M shares 10-Q · filed 2018-05-08 |
| 2017-12-31 | 1.24M shares 10-K · filed 2018-03-12 |
| 2017-09-30 | 828.82K shares 10-Q · filed 2017-11-07 |
| 2017-06-30 | 736.31K shares 10-Q · filed 2017-08-08 |
| 2017-03-31 | 636.27K shares 10-Q · filed 2017-05-09 |
| 2016-12-31 | 575.15K shares 10-K · filed 2017-03-15 |
| 2016-09-30 | 384.22K shares 10-Q · filed 2016-11-03 |
| 2016-06-30 | 208.07K shares 10-Q · filed 2016-08-11 |
| 2016-03-31 | 180.42K shares 10-Q · filed 2016-05-11 |
| 2015-12-31 | 147.67K shares 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |